Wedmont Private Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.1M Buy
16,064
+1,242
+8% +$1.27M 0.52% 31
2026
Q1
$14.1M Buy
14,822
+303
+2% +$307K 0.46% 33
2025
Q4
$16.1M Buy
14,519
+1,042
+8% +$996K 0.56% 30
2025
Q3
$11.4M Sell
13,477
-1,221
-8% -$909K 0.42% 38
2025
Q2
$11.6M Buy
14,698
+30
+0.2% +$23.3K 0.49% 37
2025
Q1
$10.7M Buy
14,668
+519
+4% +$432K 0.55% 29
2024
Q4
$11.3M Buy
14,149
+1,147
+9% +$950K 0.6% 29
2024
Q3
$11.7M Buy
13,002
+592
+5% +$532K 0.67% 27
2024
Q2
$11.8M Buy
12,410
+585
+5% +$468K 0.74% 23
2024
Q1
$8.95M Buy
11,825
+627
+6% +$446K 0.65% 25
2023
Q4
$7.01M Buy
11,198
+1,061
+10% +$619K 0.57% 30
2023
Q3
$5.8M Buy
10,137
+466
+5% +$240K 0.59% 30
2023
Q2
$4.35M Buy
9,671
+735
+8% +$308K 0.47% 34
2023
Q1
$3.28M Sell
8,936
-482
-5% -$163K 0.43% 42
2022
Q4
$3.42M Buy
9,418
+1,420
+18% +$503K 0.51% 31
2022
Q3
$2.59M Buy
7,998
+463
+6% +$147K 0.52% 33
2022
Q2
$2.44M Buy
7,535
+3,425
+83% +$1.03M 0.53% 33
2022
Q1
$1.2M Buy
4,110
+1,143
+39% +$294K 0.27% 63
2021
Q4
$741K Buy
+2,967
New +$752K 0.23% 76

Other funds holding LLY

Wedmont Private Capital's LLY Position: Q2 2026 in Review

Wedmont Private Capital increased its Eli Lilly (LLY) stake by 8.4% in Q2 2026, buying an estimated $1.27M and bringing the position to 16,064 shares worth $19.1M. The position accounts for 0.52% of the portfolio, ranked #31.

Wedmont Private Capital first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Wedmont Private Capital held 16,064 shares of Eli Lilly worth $19.1M as of Q2 2026.
  • Wedmont Private Capital bought 1,242 Eli Lilly shares in Q2 2026, an estimated $1.27M.
  • Eli Lilly made up 0.52% of Wedmont Private Capital's portfolio in Q2 2026, its #31 holding.
  • Wedmont Private Capital first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.